Prevalence and Associated Factors of Anemia in Treatment-naïve HIV-positive Subjects in Southeast Nigeria

Ernest Anyabolu^1,

¹Department of Internal Medicine, Imo State University Teaching Hospital, Orlu, Nigeria

Cite this paper:
Ernest Anyabolu. Prevalence and Associated Factors of Anemia in Treatment-naïve HIV-positive Subjects in Southeast Nigeria. American Journal of Medical Sciences and Medicine. 2016; 4(2):41-46. doi: 10.12691/ajmsm-4-2-4

Abstract

Background and Objectives: Anemia is an issue in human immunodeficiency virus (HIV) infection. This study was to determine the prevalence and associated risk factors of anemia in highly active anti-retroviral therapy (HAART)-naïve, HIV-positive subjects in Owerri, Southeast Nigeria. Methodology: This was a cross-sectional study of HAART-naïve HIV-positive subjects. Anthropometric and demographic data were collected. Hemoglobin (Hb) and other relevant investigations were performed. Anemia was defined, according to World Health Organization criteria, as Hb <13.0g/dl in males and Hb <12.0g/dl in females. Association of variables with anemia and the strength of variables to predict anemia were determined. Results: Mean Hb was 11.3±1.7g/dl in males and 11.1±1.9g/dl in females. Hb<13.0g/dl was present in 66.4% of males, while Hb<12.0g/dl was present in 67.8% of females. Overall, Hb≥12.0g/dl was present in 128(32.6%), Hb<12.0g/dl in 252(67.4%), Hb 11.0-12.0g/dl in 177(45.0%), Hb 8.0-10.9g/dl in 82(20.9%) and Hb<8.0g/dl in 6(1.5%) of the HIV subjects. Body mass index (BMI) and cluster of differentiation 4 (CD4) cells count predicted hemoglobin, while underweight, BMI, CD4 cells count <200/ml, spot urine protein (SUP) and 24-hour urine protein (24HUP) predicted anemia in HIV-positive subjects. Conclusion: The prevalence of anemia was high (67.4%) in HAART-naïve HIV-positive subjects. BMI and CD4 cells count were predictors of hemoglobin in HIV-positive subjects. CD4 cells count <200, underweight, BMI, 24HUP and SUP were predictors of anemia in HAART-naïve HIV-positive subjects. Abnormalities of weight changes and renal function were common in HAART-naïve HIV-positive subjects who were anemic in Owerri, Southeast Nigeria. Anemic HAART-naïve HIV-positive subjects should be evaluated at the early stages of the infection for underweight and renal damage.

Keywords:
HIV subjects anemia prevalence risk factors Nigeria

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	UNAIDS. Gap Report 2014. Page 26.
[2]	Anabel Ki, Jenni F: Graham Pembrey, (ed) HIV and AIDS in Africa. UNAIDS Report 2008.
[3]	Belperio PS, Rhew DC: Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 2004, 116:27-43.
[4]	Ferede G, Wondimeneh Y. Prevalence and related factors of anemia in HAART-naive HIV positive patients at Gondar University Hospital, Northwest Ethiopia BMC Hematology 2013; 13:8.
[5]	Omoregie R, Omokaro EU, Palmer O, Ogefere HO, Egbeobauwaye A, Adeghe JE, Osakue SI, Ihemeje V. Prevalence of anaemia among HIV-infected patients in Benin City, Nigeria. Tanzan J Health Res. 2009; 11(1):1-4.
[6]	Pennap GR, Abubakar K. Prevalence of Anemia among Human Immunodeficiency Virus Infected Patients Accessing Healthcare in Federal Medical Center Keffi, Nigeria. Int J Trop Dis Healt. 2015; 10(3): 1-7.
[7]	Atti.li S, Singh V, Rai M, Varma D, AK G: Hematological profile of HIV patients in relation to immune status - a hospital-based cohort from Varanasi, North India. Turk J Hematol 2008, 25: 13-19.
[8]	Lundgren JD, Mocroft A: Anemia and survival in human immunodeficiency virus. Clin Inf Dis 2003, 37:297-303.
[9]	Kyeyune R, Saathoff E, Ezeamama AE, Löscher T, Fawzi W, Guwatudde D. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect Dis. 2014; 14: 496.
[10]	Semba RD, Shah N, Klein RS. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. J Clin Infect Dis 2002, 34:260-6.
[11]	Mata-Marin JA, Gaytan-Martinez JE, Martinez-Martinez RE, Arroyo-Anduiza CI, Fuentes-Allen JL, Casarrubias-Ramirez M: Risk factors and correlates for anemia in HIV treatment-naïve infected patients: A cross-sectional analytical study. BMC Res Notes 2010, 3:230.
[12]	van der Werf MJ, van Benthem BH, van Ameijden EJ. Prevalence, incidence and risk factors of anemia in HIV-positive and HIV-negative drug users. Addiction 2000, 95:383-392.
[13]	Nadler JP, Wills TS, Somboonwit C, Vincent A, Lietz G, Marino K, Naik E, Powers S, Khan N, Almyroudis N, Laatz B. Anemia prevalence among HIV patients: antiretroviral therapy and other risk factors. Antivir Ther 2003, 8:1-4.
[14]	Masaisa F, Gahutu JB, Mukiibi J, Delanghe J, Philippé J. Anemia in Human Immunodeficiency Virus–Infected and Uninfected Women in Rwanda. Am J Trop Med Hyg 2011, 84:456-460.
[15]	Evans RH, Scadden DT: Hematological aspects of HIV infection. Baillieres Best Pract Res Clin Hematol 2000, 13: 215-230.
[16]	Ifudu O. Maximizing response to erythropoietin in treating HIV-associated anemia. Cleve Clin J Med 2001, 68:643-648.
[17]	Spivak JL: The blood in systemic disorders. Lancet 2000, 355:1707-12.
[18]	Kreuzer KA, Rockstroh JK, Jelkmann W, Theisen A, Spengler U, Sauerbruch T, et al. Inadequate erythropoietin response to anemia in HIV patients: relationship to serum levels of tumor necrosis factor-alpha, interleukin-6 and their soluble receptors. Br J Hematol 1997, 96:235-9.
[19]	Ndlovu Z, Chirwa T, Takuva S. Incidence and predictors of recovery from anemia within an HIV-infected South African Cohort, 2004-2010. Pan Afri Med J. 2014; 19:114.
[20]	Miller MF, Humphrey JH, Iliff PJ, Malaba LC, Mbuya NV, Stoltzfus RJ. Neonatal erythropoiesis and subsequent anemia in HIV-positive and HIV-negative Zimbabwean babies during the first year of life: a longitudinal study. BMC Infect Dis 2006, 6:1.
[21]	Federal Republic of Nigeria. Global AIDS Response and Progress Report 2012.
[22]	Hemoglobin concentrations for the diagnosis of anemia and assessment of severity VMNIS | Vitamin and Mineral Nutrition Information System WHO/NMH/NHD/MNM/11.1.
[23]	Amballi A, Ajibola A, Ogun SA, Ogunkolo OF, Salu LO, Oritogun KS, Oyegunle VA Demographic pattern and hematological profile in people living with HIV/AIDS in a university teaching hospital. Scientific Research and Essay. 2007; 2(8): 315-318.
[24]	Daka D, Lelissa D, Amsalu A. Prevalence of anemia before and after the initiation of antiretroviral therapy at ART centre of Hawassa University Referral Hospital, Hawassa, South Ethiopia. Scholarly J Med. 2013; 3(1): 1-6.
[25]	Rudresh K, Mysorekar TMAVV, Modepalli N, Ahuja A. Bone marrow study in patients with Human Immune Deficiency Virus and Acquired Immune Deficiency Syndrome. Brunei Int Med J. 2011; 7(3): 148-156.
[26]	Col Jyoti Kotwal, Maj Vikram Singh, Anupam Kotwal , Brig Vibha Dutta, , Maj Gen Velu Nair. A study of hematological and bone marrow changes in symptomatic patients with human immune deficiency virus infection with special mention of functional iron deficiency, anemia of critically ill and hemophagocytic lymphohistiocytosis. Med J Armed Forces India. 2013 Oct; 69(4): 319-325.
[27]	Erhabor O, Ejele OA, Nwauche CA, Buseri FI. Some hematological parameters in human immunodeficiency virus (HIV) infected Africans: the Nigerian perspective. Niger J Med. 2005; 14(1):33-8.
[28]	Ji-Yeon Bae, Ji Hyun Kwon, Pyoeng Gyun Choe, Wan Beom Park, Sung-Soo Yoon, Seonyang Park, Byoung Kook Se Youn Choi, Inho Kim, Nam Joong Kim, Seung-Ah Lee, Youn-Ak Choi Kim, Myoung-Don Oh Hematological manifestations of human immunodeficiency virus infection and the effect of highly active anti-retroviral therapy on cytopenia. Korean J Hematol. 2011; 46(4): 253-257.
[29]	Akinsegun A, Olajumoke O, Titilope A, Adewunmi A, Owolabi D, Mobolaji D, Idris D, Alaba A, Oshunkalu V. Hematologic Abnormalities in Treatment-Naïve HIV Patients. Infect Dis: Res Treat 2010; 3: 45-49.
[30]	Sujata EM, Dinesh S, Raj BY, Anjali S. Association of Hematological Profile of Human Immunodeficiency Virus-Positive Patients with Clinico-immunologic Stages of the Disease. J Lab Physicians. 2013; 5(1): 34-7.
[31]	Carolline de Araújo M; Maria de Fátima P. Militão de AlbuquerqueII; Ricardo Arraes de Alencar XI, Heloísa Ramos Lacerda de MeloI; BandeiraI F; Thaís Gelenske Braga de OliveiraIII; Érico Higino de CarvalhoIII; Adriana Paula da SilvaIV; Demócrito de Barros Miranda FilhoI. Body mass index in individuals with HIV infection and factors associated with thinness and overweight/obesity. Cad. Saúde Pública. 2011; vol.27 no.10.
[32]	Anyabolu EN, Chukwuonye II, Anyabolu AE, Enwere OO. A Study of Clinical and Biochemical Profiles of HIV Patients in Owerri, Southeast Nigeria. JMSCR. 2015; 3(12): 8643-8650.
[33]	Adewumi AA, Titilope AA, Osamuedemen VA, Vincent OO, Akinsegun OA, Dapus OD, Sulaimon AA, Prevalence of HIV-related autoimmune hemolytic anemia in Lagos, Nigeria. Nig Med J. 2014; 55(1): 63-66.
[34]	Savita RS, Veena G, Shashu L, Himanshu M, Veenu K, Ashuma S. Correlation of 2 Hour, 4 Hour and 12 Hour Urine Protein with 24 Hour Urinary Protein in Preeclampsia. J Family Reprod Heath. 2014 Set, 8(3): 131-134.